Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsEmpire Bluecross Saphnelo Prior Auth | OpenPayer
    Ask Trek AI about this page
    ModifiedEmpire BluecrossPolicy CC-0202

    Saphnelo (anifrolumab-fnia) for systemic lupus erythematosus

    Customize your policy alerts

    Sign up for Empire Bluecross Policy CC-0202 alerts

    Get alerted when Policy CC-0202 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs medical-necessity and prior-authorization review for Saphnelo (anifrolumab-fnia) used to treat adults with moderate to severe systemic lupus erythematosus as add-on therapy, including applicable coding and quantity limits.

    Policy Summary
    PayerEmpire Bluecross
    PolicySaphnelo (anifrolumab-fnia) for systemic lupus erythematosus
    Policy CodePolicy CC-0202
    Change TypeModified
    Effective DateJul 28, 2026
    Last ReviewJun 8, 2026
    Next Review DateN/A
    Key ActionSubmit documentation of an SLE diagnosis according to American College of Rheumatology criteria, including positive ANA titer of at least 1:80 or anti-dsDNA of at least 30 IU/mL.
    SourceLink
    POLICY UPDATE CHANGES

    A Saphnelo 120 mg/0.8 mL syringe or autoinjector quantity limit was added.

    HCPCS C9399 and J3590 were added for Saphnelo supplied as a subcutaneous product.

    The restriction against using Saphnelo with cyclophosphamide was removed.

    The diagnosis requirement for systemic lupus erythematosus was clarified to require American College of Rheumatology criteria and supporting antibody documentation.

    18+Minimum age for initial therapy
    SLEDAI-2K ≥6Required active disease threshold

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    30 daysMinimum duration of active disease
    6 monthsInitial approval duration
    1 yearContinuation approval duration
    1 vial/28 daysQuantity limit for 300 mg/2 mL vial

    Coverage Criteria

    Initial Therapy

    Covered when ALL of the following initial-therapy criteria are met.

    • Age: Individual is 18 years of age or older>=18 years
    • SLE diagnosis: Individual has systemic lupus erythematosus diagnosed according to American College of Rheumatology criteria
    • Active moderate-to-severe disease: Disease is moderate to severe and active while the individual is on the current treatment regimen for SLESLEDAI-2K >=6

      Documentation required

    • Serologic verification: The diagnosis is verified by a history of positive anti-nuclear antibody testing or anti-dsDNA testingANA >=1:80 or anti-dsDNA >=30 IU/mL

      Documentation required

    • Persistent activity despite standard therapy: SLE remains active while receiving corticosteroids, antimalarials, or immunosuppressants alone or in combination for at least the last 30 days>=30 days
    • Combination therapy: Saphnelo is used in combination with standard therapy, such as corticosteroids, antimalarials, and/or immunosuppressants

      Not with other biologics or cyclophosphamide

    Continuation Therapy

    Covered when ALL of the following continuation-therapy criteria are met.

    • Therapeutic response: Documentation shows improvement in disease activity following treatment with Saphnelo, indicating a therapeutic response

      Documentation required

    • No severe active CNS lupus: Individual has no evidence of severe active central nervous system lupus, such as psychosis or seizures
    • No severe active lupus nephritis: Individual has no evidence of severe active lupus nephritisProteinuria <=6 gm/d, serum creatinine <=2.5 mg/dL, and no dialysis requirement
    • Combination therapy:

    Coverage may not be approved when the individual has severe active central nervous system lupus, including manifestations such as psychosis or seizures.

    Coverage may not be approved when the individual has severe active lupus nephritis, defined as proteinuria greater than 6 gm/d, serum creatinine greater than 2.5 mg/dL, or a requirement for dialysis.

    Coverage may not be approved when Saphnelo is used with another biologic, including B-cell targeted therapies or belimumab, or when it is used with voclosporin.

    Coverage may not be approved for individuals with human immunodeficiency virus (HIV) infection, hepatitis B virus infection, or hepatitis C virus infection.

    Coding and Clinical Thresholds

    HCPCSHCPCS
    C9399Unclassified drugs or biologicals [when specified as Saphnelo (anifrolumab-fnia) subcutaneous (SC)]
    J0491Injection, anifrolumab-fnia, 1 mg [Saphnelo intravenous (IV)]
    J3590Unclassified biologics [when specified as Saphnelo (anifrolumab-fnia) subcutaneous (SC)]
    ICD-10 DiagnosisICD-10
    M32.0-M32.9Systemic lupus erythematosus (SLE)
    SLEDAI-2K Threshold
    SLEDAI-2K thresholdGreater than or equal to 6
    Disease statusModerate-to-severe active systemic lupus erythematosus
    Assessment timingWhile on the current SLE treatment regimen
    ANA Titer Threshold
    ANA titer thresholdGreater than or equal to 1:80
    PurposeVerification of the systemic lupus erythematosus diagnosis
    Documentation

    Prior Authorization and Documentation

    Prior Authorization

    Initial Prior Authorization

    Prior authorization is required for initial Saphnelo requests. Submit clinical documentation demonstrating that all initial-therapy criteria are met, including age, diagnosis, disease severity and activity, treatment history, and concurrent standard therapy.

    • Individual is 18 years of age or older.
    • Initial approval duration is 6 months.
    Prior Authorization

    Continuation Prior Authorization

    Continuation requests may be approved only when all continuation criteria are documented, including therapeutic response, absence of specified severe disease, and use with standard therapy. Continuation approval duration is 1 year.

    • Document improvement in disease activity following treatment with Saphnelo, indicating a therapeutic response.
    • Confirm no severe active central nervous system lupus and no severe active lupus nephritis.
    • Confirm use with standard therapy, such as corticosteroids, antimalarials, and/or immunosuppressants; do not combine with other biologics.

    Therapy Background

    Saphnelo (anifrolumab-fnia) is an intravenously administered type I interferon receptor antagonist used as add-on therapy with standard treatment for adults with moderate to severe systemic lupus erythematosus. Standard background therapy may include corticosteroids, antimalarials, and immunosuppressants.

    Clinical Definitions

    American College of Rheumatology SLE Criteria
    Classification requirementFour of 11 criteria
    TimingCriteria may be met simultaneously or in succession
    Criteria includeMalar rash, discoid rash, photosensitivity, oral ulcers, arthritis, serositis, renal disorder, neurological disorder, hematological disorder, immunological disorder, and anti-nuclear antibody
    SELENA-SLEDAI
    Type of measureWeighted index of lupus disease activity
    Assessment componentsSigns and symptoms, laboratory tests, and physician assessment
    Scoring range

    Initial Therapy Criteria

    Initial Therapy

    Initial requests may be approved when all criteria are met.

    • Age: Individual is 18 years of age or older>=18 years
    • SLE diagnosis: Individual has systemic lupus erythematosus diagnosed according to American College of Rheumatology criteria
    • Active moderate-to-severe disease: Disease is moderate to severe and active while the individual is on the current treatment regimen for SLESLEDAI-2K >=6

      Documentation required

    Continuation Criteria

    Continuation Therapy

    Continuation requests may be approved when all criteria are met.

    • Therapeutic response: Documentation shows improvement in disease activity following treatment with Saphnelo, indicating a therapeutic response

      Documentation required

    • No severe active CNS lupus: Individual has no evidence of severe active central nervous system lupus, such as psychosis or seizures
    • No severe active lupus nephritis: Individual has no evidence of severe active lupus nephritisProteinuria <=6 gm/d, serum creatinine <=2.5 mg/dL, and no dialysis requirement

    Quantity Limits

    Saphnelo 300 mg/2 mL Vial
    ProductSaphnelo (anifrolumab-fnia) 300 mg/2 mL vial
    Quantity limit1 vial
    Limit periodPer 28 days
    Saphnelo 120 mg/0.8 mL Syringe or Autoinjector
    ProductSaphnelo (anifrolumab-fnia) 120 mg/0.8 mL syringe/autoinjector
    Quantity limit4 syringes/autoinjectors
    Limit periodPer 28 days
    Policy Summary
    PayerEmpire Bluecross
    PolicySaphnelo (anifrolumab-fnia) for systemic lupus erythematosus
    Policy CodePolicy CC-0202
    Change TypeModified
    Effective DateJul 28, 2026
    Last ReviewJun 8, 2026
    Next Review DateN/A
    Key ActionSubmit documentation of an SLE diagnosis according to American College of Rheumatology criteria, including positive ANA titer of at least 1:80 or anti-dsDNA of at least 30 IU/mL.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Clinical ThresholdsPrior Authorization and DocumentationTherapy BackgroundClinical DefinitionsInitial Therapy CriteriaContinuation CriteriaQuantity Limits
    Saphnelo is used in combination with standard therapy, such as corticosteroids, antimalarials, and/or immunosuppressants

    Not with other biologics

    History of a positive anti-nuclear antibody test
    Anti-dsDNA Threshold
    Anti-dsDNA thresholdGreater than or equal to 30 IU/mL
    PurposeVerification of the systemic lupus erythematosus diagnosis
    DocumentationHistory of a positive anti-dsDNA test
    Severe Lupus Nephritis: Proteinuria
    Proteinuria thresholdGreater than 6 gm/d
    ConditionSevere active lupus nephritis
    Coverage implicationSaphnelo may not be approved when this threshold is met
    Severe Lupus Nephritis: Serum Creatinine
    Serum creatinine thresholdGreater than 2.5 mg/dL
    ConditionSevere active lupus nephritis
    Coverage implicationSaphnelo may not be approved when this threshold is met
    Documentation Required

    SLE Diagnosis and Antibody Verification

    Document systemic lupus erythematosus according to American College of Rheumatology (ACR) criteria and verify the diagnosis with a qualifying positive antibody result.

    • Provide documentation of an ACR-confirmed diagnosis of systemic lupus erythematosus.
    • Document a positive anti-nuclear antibody (ANA) titer of ≥ 1:80 or anti-dsDNA of ≥ 30 IU/mL.
    Documentation Required

    Active Disease Severity

    For an initial request, document that the disease is moderate to severe and active while the individual is on the current SLE treatment regimen.

    • Provide a SLEDAI-2K score of ≥ 6.
    Documentation Required

    Persistent Activity Despite Standard Therapy

    Document that SLE remains active despite treatment with corticosteroids, antimalarials, or immunosuppressants, used alone or in combination, for at least the preceding 30 days.

    • Provide evidence of ongoing disease activity while on the applicable standard therapy.
    • Saphnelo must be used in combination with standard therapy, including corticosteroids, antimalarials, and/or immunosuppressants; initial criteria exclude combination with other biologics or cyclophosphamide.
    Documentation Required

    Continuation Response and Safety Documentation

    For continuation, document improvement in disease activity after Saphnelo treatment and confirm that the individual continues to meet safety and combination-therapy requirements.

    • Document a therapeutic response demonstrated by improvement in disease activity.
    • Confirm no severe active central nervous system lupus, such as psychosis or seizures.
    • Confirm no severe active lupus nephritis, defined as proteinuria > 6 gm/d, serum creatinine > 2.5 mg/dL, or a need for dialysis.
    • Confirm ongoing use with standard therapy and no combination with other biologics.
    Denial Risk

    Explicit Non-Approval Conditions

    Saphnelo may not be approved when any listed exclusion condition is present. Screen for and document the absence of these conditions before submitting or renewing authorization.

    • Severe active central nervous system lupus, such as psychosis or seizures.
    • Severe active lupus nephritis, defined as proteinuria > 6 gm/d, serum creatinine > 2.5 mg/dL, or requiring dialysis.
    • Use in combination with another biologic, including B-cell-targeted therapies or belimumab, or with voclosporin.
    • Human immunodeficiency virus (HIV), hepatitis B virus, or hepatitis C virus infection.
    Maximum theoretical score of 105; 0 indicates inactive disease
    SLEDAI-2K
    DefinitionModification of the SLEDAI disease-activity index
    Documentation supportedPersistent disease activity
    Examples of persistent activityRash, alopecia, mucosal ulcers, and proteinuria
    Lupus Nephritis
    DefinitionKidney inflammation associated with systemic lupus erythematosus
    Potential consequenceIrreversible kidney damage
    Severe outcomesEventual need for dialysis or kidney transplant when SLE is poorly controlled
    Serologic verification: The diagnosis is verified by a history of positive anti-nuclear antibody testing or anti-dsDNA testingANA >=1:80 or anti-dsDNA >=30 IU/mL

    Documentation required

  1. Persistent activity despite standard therapy: SLE remains active while receiving corticosteroids, antimalarials, or immunosuppressants alone or in combination for at least the last 30 days>=30 days
  2. Combination therapy: Saphnelo is used in combination with standard therapy, such as corticosteroids, antimalarials, and/or immunosuppressants

    Not with other biologics or cyclophosphamide

  3. Combination therapy: Saphnelo is used in combination with standard therapy, such as corticosteroids, antimalarials, and/or immunosuppressants

    Not with other biologics